- /
- Supported exchanges
- / US
- / EVMN.NYSE
Evommune, Inc. (EVMN NYSE) stock market data APIs
Evommune, Inc. Financial Data Overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Evommune, Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only €19.99
Get Evommune, Inc. data using free add-ons & libraries
Get Evommune, Inc. Fundamental Data
Evommune, Inc. Fundamental data includes:
- Net Revenue: 10 000 K
- EBITDA: -100 356 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.68
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evommune, Inc. News
New
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-sever...
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Karyopharm T...
Sector Update: Healthcare Stocks Decline in Afternoon Trading
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Thursday 7/9 Insider Buying Report: LRMR, EVMN
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only €19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.